L aNova Medicines and AstraZeneca sign global exclusive licence agreement for preclinical ADC
Chinese biotechnology company LaNova Medicines and UK-based pharma company AstraZeneca have announced that they have signed a global exclusive licence agreement for a preclinical stage antibody drug conjugate (ADC).
LM-305 targets G protein-coupled receptor, class C, group 5, member D (GPRC5D). It consists of an anti-GRPC5D monoclonal antibody, a protease-degradable linker and a cytotoxic payload monomethyl auristatin E (MMAE). It is indicated for use in patients with multiple myeloma.
Within the agreement, AstraZeneca will be granted full exclusive global licence to research, develop and commercialise LM-305. LaNova will be eligible for upfront and near-term payments of up to $55m, as well as additional development and commercial milestone payments of up to $545m and tiered royalties on net sales.
Dr Crystal Qin, founder, chairman and CEO of LaNova Medicines commented: “LaNova Medicines has a strong focus on discovering and developing innovative medicines in the ADC and immuno-oncology fields. We’re excited to reach this agreement with AstraZeneca. With the potential to become a first-in-class GPRC5D-directed ADC for multiple myeloma, LM-305 exemplifies our innovative and robust platform for ADC development. This agreement is further recognition of our exceptional pipeline assets and R&D capabilities. We are confident that AstraZeneca is the ideal company to advance LM-305 for the betterment of patients globally.”
Nina Shah, global head of multiple myeloma, Haematology R&D at AstraZeneca, said: “We are pleased to have the opportunity to advance the development of LM-305, a novel GPRC5D-targeting ADC, as a potential new treatment option for relapsed/refractory multiple myeloma. LM-305 advances our leadership in ADCs and enriches our growing Haematology pipeline, helping us deliver against our broader ambition to transform clinical outcomes for patients living with blood cancers.”
Pharmaceutical Industry news, analysis and insights